Combination antifungal therapy against Candida species

The new frontier - Are we there yet?

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

In the past decade, we have seen a significant increase in the incidence of invasive fungal infections. In addition, opportunistic fungal infections resistant to antifungal agents have become increasingly common and their frequency will more than likely continue to increase. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. The unique properties of newer antifungals now provide us with the opportunity to investigate antifungal combinations that may become the standard of care for serious fungal infections. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against Candida in clinical trials. On the other hand, caution is still needed since other antifungal combinations have demonstrated antagonistic activity in vitro. Well-controlled clinical trials are needed to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side effect potential of combination regimens and the pharmacoeconomic impact these regimens may have. Thus, while much optimism exists for combination therapy, there is much yet to be done.

Original languageEnglish (US)
Pages (from-to)355-368
Number of pages14
JournalMedical Mycology
Volume41
Issue number5
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Mycoses
Candida
therapeutics
antifungal agents
infection
Fungal Drug Resistance
clinical trials
Pharmaceutical Economics
Antifungal Agents
Opportunistic Infections
Controlled Clinical Trials
Therapeutics
Standard of Care
drug resistance
new combination
Clinical Trials
mechanism of action
adverse effects
Mortality
Incidence

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • veterinary(all)
  • Microbiology

Cite this

Combination antifungal therapy against Candida species : The new frontier - Are we there yet? / Vazquez, Jose Antonio.

In: Medical Mycology, Vol. 41, No. 5, 01.10.2003, p. 355-368.

Research output: Contribution to journalReview article

@article{02ed5133c0ff44a689ac8e5264af47d1,
title = "Combination antifungal therapy against Candida species: The new frontier - Are we there yet?",
abstract = "In the past decade, we have seen a significant increase in the incidence of invasive fungal infections. In addition, opportunistic fungal infections resistant to antifungal agents have become increasingly common and their frequency will more than likely continue to increase. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. The unique properties of newer antifungals now provide us with the opportunity to investigate antifungal combinations that may become the standard of care for serious fungal infections. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against Candida in clinical trials. On the other hand, caution is still needed since other antifungal combinations have demonstrated antagonistic activity in vitro. Well-controlled clinical trials are needed to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side effect potential of combination regimens and the pharmacoeconomic impact these regimens may have. Thus, while much optimism exists for combination therapy, there is much yet to be done.",
author = "Vazquez, {Jose Antonio}",
year = "2003",
month = "10",
day = "1",
doi = "10.1080/13693780310001616528",
language = "English (US)",
volume = "41",
pages = "355--368",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Combination antifungal therapy against Candida species

T2 - The new frontier - Are we there yet?

AU - Vazquez, Jose Antonio

PY - 2003/10/1

Y1 - 2003/10/1

N2 - In the past decade, we have seen a significant increase in the incidence of invasive fungal infections. In addition, opportunistic fungal infections resistant to antifungal agents have become increasingly common and their frequency will more than likely continue to increase. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. The unique properties of newer antifungals now provide us with the opportunity to investigate antifungal combinations that may become the standard of care for serious fungal infections. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against Candida in clinical trials. On the other hand, caution is still needed since other antifungal combinations have demonstrated antagonistic activity in vitro. Well-controlled clinical trials are needed to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side effect potential of combination regimens and the pharmacoeconomic impact these regimens may have. Thus, while much optimism exists for combination therapy, there is much yet to be done.

AB - In the past decade, we have seen a significant increase in the incidence of invasive fungal infections. In addition, opportunistic fungal infections resistant to antifungal agents have become increasingly common and their frequency will more than likely continue to increase. The antifungal armamentarium for the treatment of serious fungal infections remains limited. A possible approach to overcoming antifungal drug resistance and high mortality rates seen in severe fungal infections is to combine two or three classes of antifungals, especially if the drugs have different mechanisms of action. The unique properties of newer antifungals now provide us with the opportunity to investigate antifungal combinations that may become the standard of care for serious fungal infections. Combinations of new agents along with more traditional antifungals have now been shown to possess some synergistic or at least additive activity against Candida in clinical trials. On the other hand, caution is still needed since other antifungal combinations have demonstrated antagonistic activity in vitro. Well-controlled clinical trials are needed to define the most efficacious antifungal regimen. Furthermore, these trials should also evaluate the side effect potential of combination regimens and the pharmacoeconomic impact these regimens may have. Thus, while much optimism exists for combination therapy, there is much yet to be done.

UR - http://www.scopus.com/inward/record.url?scp=0344013465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344013465&partnerID=8YFLogxK

U2 - 10.1080/13693780310001616528

DO - 10.1080/13693780310001616528

M3 - Review article

VL - 41

SP - 355

EP - 368

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 5

ER -